Article Versions Notes

Berger M, Thueringer A, Franz D, Dandachi N, Talakić E, Richtig G, Richtig E, Rohrer PM, Koch L, Wolf IH, et al. Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study. Cancers. 2021; 13(12):3101. https://doi.org/10.3390/cancers13123101

Berger, Marina, Andrea Thueringer, Doritt Franz, Nadia Dandachi, Emina Talakić, Georg Richtig, Erika Richtig, Peter Michael Rohrer, Lukas Koch, Ingrid Hildegard Wolf, and et al. 2021. "Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study" Cancers 13, no. 12: 3101. https://doi.org/10.3390/cancers13123101

Berger, M., Thueringer, A., Franz, D., Dandachi, N., Talakić, E., Richtig, G., Richtig, E., Rohrer, P. M., Koch, L., Wolf, I. H., Koch, C., Rainer, B. M., Koeller, M., Pichler, M., Gerritsmann, H., Kashofer, K., & Aigelsreiter, A. (2021). Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study. Cancers, 13(12), 3101. https://doi.org/10.3390/cancers13123101